Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-801 in Recurrent Glioblastoma
NCT05222802Phase 1Active, not recruiting
- Sponsor
- Katmai Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ERAS-801 in glioblastoma multiforme (GBM) (2 arms), sponsored by Katmai Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 2 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
ERAS-801
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05222802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222802.